X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Lonsurf (trifluridine/tipiracil), an oral nucleoside antitumor agent, got approved as a single agent or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (mCRC).
Lead Product(s): Trifluridine,Tipiracil Hydrochloride,Bevacizumab
Therapeutic Area: Oncology Product Name: Lonsurf
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2023
Details:
Lonsurf consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil, it has demonstrated anti-tumor activity against refractory colorectal cancer, in combination with bevacizumab.
Lead Product(s): Trifluridine,Tipiracil Hydrochloride,Bevacizumab
Therapeutic Area: Oncology Product Name: Lonsurf
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
The collaboration focuses on the development of two antibody candidates, UCB6114 and UCB4594 by bringing together the oncology-focused translational research and clinical development capabilities of Cancer Research UK, and UCB’s renowned antibody discovery expertise.
Lead Product(s): UCB6114,Trifluridine,Tipiracil Hydrochloride
Therapeutic Area: Oncology Product Name: UCB6114
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: UCB Pharma S.A
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 09, 2023
Details:
Lonsurf is an oral nucleoside antitumor agent which consists trifluridine, and tipiracil (TP inhibitor), which increases trifluridine exposure by inhibiting its metabolism by TP. Trifluridine results in DNA dysfunction and inhibition of cell proliferation.
Lead Product(s): Trifluridine,Tipiracil Hydrochloride,Bevacizumab
Therapeutic Area: Oncology Product Name: Lonsurf
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taiho Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
Lonsurf (trifluridine) and tipiracil consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase (TP) inhibitor, tipiracil, which increases trifluridine exposure by inhibiting its metabolism by TP.
Lead Product(s): Trifluridine,Tipiracil Hydrochloride
Therapeutic Area: Oncology Product Name: Lonsurf
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taiho Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
Investigators will combine Natrunix and trifluridine/tipiracil as a new candidate therapy for metastatic colorectal cancer in subjects that have failed earlier treatment with oxaliplatin, irinotecan, and fluoropyrimidine.
Lead Product(s): XB2001,Trifluridine,Tipiracil Hydrochloride
Therapeutic Area: Oncology Product Name: Natrunix
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: The French National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding April 28, 2022
Details:
Natco Pharma launched novel fixed-dose combination of Trifluridine+Tipiracil under the brand name Tipanat, is a novel antineoplastic nucleoside analog indicated for the treatment of advanced colorectal and gastric cancer.
Lead Product(s): Trifluridine,Tipiracil Hydrochloride
Therapeutic Area: Oncology Product Name: Tipanat
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2021
Details:
Data for LONSURF® (trifluridine and tipiracil) in previously treated patients with metastatic gastric cancer and metastatic gastroesophageal junction adenocarcinoma will be presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
Lead Product(s): Trifluridine,Tipiracil Hydrochloride
Therapeutic Area: Oncology Product Name: Lonsurf
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Servier
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021
Details:
Data include pooled safety analysis of Phase III trials of LONSURF in patients with metastatic colorectal cancer and metastatic gastric junction cancer, updates on futibatinib trials in progress.
Lead Product(s): Trifluridine,Tipiracil Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
